Skyrizi and homocysteine: the research question

The idea to explore

A guide to a chapter asking whether IL-23 inhibition could have implications for homocysteine-related inflammatory pathways.

Follow the connections

The source discusses risankizumab, the drug known as Skyrizi, in the context of inflammatory disease and then extends the discussion to a proposed homocysteine connection. Its own introduction acknowledges the lack of direct trials evaluating homocysteine regulation.

A proposed new use needs its own evidence

This chapter illustrates how a research hypothesis develops: start with a drug that affects one pathway, identify a possible connection to another condition, then ask whether the connection produces a benefit. Each step is a new question. Success in one inflammatory disease is not proof of benefit for homocysteine regulation. The source itself identifies the absence of direct trials, so this discussion is best read as a research question rather than a treatment option established by the chapter.

A question for your next conversation

Is there a trial in the condition being discussed, with the outcome we care about?

LET YOUR CURIOSITY LEAD

One idea opens another.

Choose a subject to find the related teaching across videos, articles, courses and references.